The study will be conducted in three phases. Part A is a Phase 2, open-label, semi-sequential dose-ranging portion of the study. Part B is the Phase 3, double-blind, randomized, placebo controlled ...
Welcome to the Crinetics Pharmaceuticals Corporate Update Conference Call. [Operator Instructions] I will now turn the call over to Gayathri Diwakar, Head of Investor Relations. Please go ahead. Thank ...
The diagnosis of polycystic ovary syndrome, a common hyperandrogenic disorder, requires the exclusion of several diseases that might show similar symptoms at presentation, for example nonclassical ...
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs.
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced PALSONIFY U.S. unaudited and preliminary net product revenue of over $5 million for ...
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 ...
A high proportion of cases of congenital adrenal hyperplasia (CAH) are attributable to deficiency of 21-hydroxylase, which results in presentation of ambiguous genitalia at birth in girls but with no ...
Primary aldosteronism management depends on a multitude of factors, and surgical adrenalectomy is generally recommended in ...
The following slide deck was published by Crinetics Pharmaceuticals, Inc. in conjunction with this event.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback